Skip to main content

Lifecycle of a Medical Device in the USA

The regulatory lifecycle of a medical device under FDA encompasses three main phases: pre-market, market entry, and post-market.

Phase 1 — Pre-market​

Step 1: Determine regulatory status​

  • Is your product a medical device under FD&C Act §201(h)?
  • Does CDRH or CBER have jurisdiction?
  • Is it a combination product requiring an RFD?

Step 2: Classify your device​

Step 3: Determine the market pathway​

  • Class I (most) → General controls only; many are 510(k)-exempt
  • Class II (most) → 510(k) clearance
  • Class I/II (novel) → De Novo classification request
  • Class III → Premarket Approval (PMA)

Step 4: Establish your Quality System​

  • Implement 21 CFR Part 820 (QMSR) / ISO 13485-aligned QMS
  • Establish design controls, device history records, risk management

Step 5: Gather clinical / technical evidence​

  • Bench testing, biocompatibility, software validation
  • Clinical data (IDE study in USA or acceptance of foreign data)

Step 6: Submit to FDA​

  • 510(k), De Novo request, or PMA
  • Use eSTAR electronic submission format
  • Respond to FDA additional information (AI) requests

Phase 2 — Market entry​

Step 7: Establish registration and device listing​

  • Register your establishment annually at FURLS/CDRH portal
  • List all devices you manufacture or import for US commerce

Step 8: Comply with UDI requirements​

  • Obtain a Device Identifier (DI) from an FDA-accredited issuing agency
  • Label your device with the UDI
  • Submit device information to GUDID (Global UDI Database)

Step 9: Ensure labelling compliance​

  • Adequate directions for use (21 CFR Part 801)
  • Prescription or OTC designation
  • Required warnings and precautions

Phase 3 — Post-market​

Step 10: MDR obligations​

  • Monitor complaints and adverse events
  • Report deaths and serious injuries within required timeframes
  • Submit MDRs via eMDR system

Step 11: Recalls and corrections​

  • Report corrections and removals under 21 CFR Part 806
  • Conduct recalls in accordance with FDA expectations
  • Cooperate with FDA-initiated recall actions

Step 12: Maintain quality system​

  • Ongoing CAPA, internal audits, management reviews
  • Respond to FDA inspections and 483 observations

Step 13: Post-market surveillance​

  • Comply with any §522 post-market surveillance study orders
  • Maintain distribution records

Step 14: Manage changes​

  • Evaluate design and labelling changes against 510(k)/PMA filing thresholds
  • Submit supplements or new 510(k)s when required

Official resources​